Antithrombotic Drugs in Cirrhosis

1. Flores B, Trivedi HD, Robson SC, Bonder A. Hemostasis, bleeding and thrombosis in liver disease. Journal of translational science. 2017;3(3).10.15761/JTS.1000182613643530221012Search in Google Scholar

2. Buresi M, Hull R, Coffin CS. Venous thromboembolism in cirrhosis: a review of the literature. Canadian Journal of Gastroenterology and Hepatology. 2012;26(12):9058.10.1155/2012/175849Search in Google Scholar

3. Dhar A, Mullish BH, Thursz MR. Anticoagulation in chronic liver disease. Journal of hepatology. 2017;66(6):131326.10.1016/j.jhep.2017.01.00628088580Search in Google Scholar

4. Stine JG, Intagliata NM, Shah NL, Lisman T, Violi F, Caldwell SH, et al. Clinical Cirrhosis Dilemmas: Survey of Practice from the 7th International Coagulation in Liver Disease Conference. Digestive Diseases and Sciences. 2019;16.10.1007/s10620-019-05884-0716002431628574Search in Google Scholar

5. Villa and E, De Maria N. Anticoagulation in cirrhosis. Liver international. 2012;32(6):8789.10.1111/j.1478-3231.2012.02825.xSearch in Google Scholar

6. Rank KM, Lake J. COn: anticoagulation for Portal vein Thrombosis in advanced Cirrhosis. Clinical liver disease. 2018;12(3):80.10.1002/cld.713638591230988916Search in Google Scholar

7. Søgaard KK, Horváth-Puhó E, Grønbæk H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based casecontrol study. The American journal of gastroenterology. 2009;104(1):96.10.1038/ajg.2008.3419098856Search in Google Scholar

8. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB. 2009;11(6):45964.10.1111/j.1477-2574.2009.00079.x275663119816608Search in Google Scholar

9. Aggarwal A, Puri K, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review. World journal of gastroenterology: WJG. 2014;20(19):5737.10.3748/wjg.v20.i19.5737402478424914335Search in Google Scholar

10. Weinberg EM, Palecki J, Reddy KR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. In Thieme Medical Publishers; 2019. p. 195208.10.1055/s-0039-167993430978730Search in Google Scholar

11. Kalambokis GN, Baltayiannis G, Christodoulou D. von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis. World journal of gastroenterology. 2016;22(19):4786.10.3748/wjg.v22.i19.4786487008627217711Search in Google Scholar

12. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5): 125360.10.1053/j.gastro.2012.07.01822819864Search in Google Scholar

13. To UK, Garcia-Tsao G. PrO: Patients With advanced Cirrhosis and Portal vein Thrombosis should receive anticoagulation. Clinical liver disease. 2018;12(3):74.10.1002/cld.717638591830988915Search in Google Scholar

14. Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver International. 2014;34(1):2632.10.1111/liv.1221123758818Search in Google Scholar

15. Chokesuwattanaskul R, Thongprayoon C, Bathini T, Torres-Ortiz A, O’Corragain OA, Watthanasuntorn K, et al. Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta-analysis. Digestive and Liver Disease. 2019;51(4):48995.10.1016/j.dld.2018.12.00130594462Search in Google Scholar

16. Dhar A, Sadiq F, Anstee QM, Levene AP, Goldin RD, Thursz MR. Thrombin and factor Xa link the coagulation system with liver fibrosis. BMC gastroenterology. 2018;18(1):60.10.1186/s12876-018-0789-8594165829739329Search in Google Scholar

17. Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis Possibilities and caveats. Journal of hepatology. 2013;59(2):35866.10.1016/j.jhep.2013.03.02723548197Search in Google Scholar

18. Youngwon N, Kim J-E, Lim HS, Han K-S, Kim HK. Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay. BioMed research international. 2013;2013.10.1155/2013/856754359510723555099Search in Google Scholar

19. Li C-J, Yang Z-H, Shi X-L, Liu D-L. Effects of aspirin and enoxaparin in a rat model of liver fibrosis. World journal of gastroenterology. 2017;23(35):6412.10.3748/wjg.v23.i35.6412564326629085190Search in Google Scholar

20. Gallagher C, Sanders P, Wong CX. Anticoagulation for Atrial Fibrillation in Cirrhosis of the Liver: Are Low-Dose Non-Vitamin K Oral Anticoagulants a Reasonable Alternative to Warfarin? 2019;10.1161/JAHA.119.012102647492730834801Search in Google Scholar

21. EASL E. EASO. Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease, Obes Facts. 2016;9:6590.10.1159/000443344Search in Google Scholar